Patient Data,
Patient Safety.

The Security Rule (45 CFR Part 164 Subpart C) does not name penetration testing as a specific implementation specification. What it does require is the Security Risk Analysis under §164.308(a)(1)(ii)(A) — "an accurate and thorough assessment of the potential risks and vulnerabilities to the confidentiality, integrity and availability of electronic protected health information". OCR settlement actions over the past decade have repeatedly cited the absence or inadequacy of that risk analysis as the primary failing. A credible risk analysis requires technical evidence — vulnerability assessment, penetration testing, configuration review — that the controls implemented under §164.308, §164.310 and §164.312 actually work in production.

The Ayushman Bharat Digital Mission (ABDM) operates the national digital health ecosystem — ABHA (health ID), Healthcare Professionals Registry, Health Facility Registry, Personal Health Records, Unified Health Interface and the consent-management framework. Integration with ABDM is governed by the National Health Authority's technical and security guidelines, which prescribe authentication, encryption, consent capture, audit-logging and breach-notification obligations beyond those in the DPDP Act. Engagements that touch ABDM endpoints scope the NHA security guidelines alongside the broader DPDP Act 2023 obligations on personal sensitive data.

Health data is personal data under the DPDP Act. Healthcare providers and healthtech platforms processing patient records become Data Fiduciaries with obligations on lawful processing, consent capture, purpose limitation, data minimisation, accuracy, retention, breach notification to the Data Protection Board of India and to affected Data Principals, and (if classified) the additional obligations of a Significant Data Fiduciary. Penalties run up to INR 250 crore per breach. Most US-style HIPAA controls (encryption, access control, audit logging, retention) carry through; the structural difference is the consent architecture and the cross-border transfer regime.

Yes. Medical devices that connect to a network — infusion pumps, patient monitors, imaging systems, surgical robots, implantable devices with wireless interfaces — operate under FDA premarket cybersecurity guidance for device makers selling into the US, plus the underlying Quality System Regulation under 21 CFR Part 820. Premarket submissions need a documented Secure Product Development Framework, a Software Bill of Materials, threat modelling, a vulnerability management plan, security testing including penetration testing, and post-market vulnerability handling commitments. AxVeil engagements for device makers cover the device firmware, the wireless interfaces, the supporting cloud back-end and the clinician-facing apps as one threat-modelled system.

Five-step model. First, inventory the data — electronic protected health information categories, the entities they flow between, the lawful basis for processing under HIPAA / DPDP / GDPR. Second, map the trust boundaries — patient device, hospital network, clinician workstation, EMR / HIS, cloud back-end, third-party labs and pharmacies. Third, enumerate the threat actors — financially motivated ransomware crews (the dominant healthcare actor on the public record), insider misuse, supply-chain compromise, nation-state where the patient population is sensitive. Fourth, drive STRIDE against each trust boundary. Fifth, score residual risk and propose mitigations. The engagement scope is built to test the highest-residual-risk paths.

Yes. Default posture for hospital and clinical environments is non-disruptive: read-only payloads, throttled request rates, no destructive testing of clinical workflows or biomedical equipment in operational use, no automated exploits that could affect patient-care decisions. Where active testing of devices is necessary — typically pre-deployment validation or an isolated test environment — we run it on lab clones with the biomedical engineering team in the loop. Rules of Engagement explicitly exclude any test that could cause clinical decision support to mis-alert or mis-route during the engagement window.